CGTX - Dividend announcements

- SHINE Alzheimer's Trial Expands to European Sites - - SEQUEL Alzheimer's Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active - PURCHASE, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (NASDAQ:CGTX), (the "Company" or "Cognition") today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company's business and clinical development progress. "We continue to advance three Phase 2 clinical trials investigating CT1812 and are highly motivated by the encouraging data from our clinical programs as well as favorable results from complementary approaches bei

Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators PURCHASE, N.Y., May 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2022 and provided recent business updates. "Throughout the first quarter, we contin